974 related articles for article (PubMed ID: 29787859)
1. Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease.
Scorletti E; Afolabi PR; Miles EA; Smith DE; Almehmadi A; Alshathry A; Moyses HE; Clough GF; Wright M; Patel J; Bindels L; Delzenne NM; Calder PC; Byrne CD
Contemp Clin Trials; 2018 Aug; 71():113-123. PubMed ID: 29787859
[TBL] [Abstract][Full Text] [Related]
2. Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.
Scorletti E; Afolabi PR; Miles EA; Smith DE; Almehmadi A; Alshathry A; Childs CE; Del Fabbro S; Bilson J; Moyses HE; Clough GF; Sethi JK; Patel J; Wright M; Breen DJ; Peebles C; Darekar A; Aspinall R; Fowell AJ; Dowman JK; Nobili V; Targher G; Delzenne NM; Bindels LB; Calder PC; Byrne CD
Gastroenterology; 2020 May; 158(6):1597-1610.e7. PubMed ID: 31987796
[TBL] [Abstract][Full Text] [Related]
3. Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial.
Bogovič Matijašić B; Obermajer T; Lipoglavšek L; Sernel T; Locatelli I; Kos M; Šmid A; Rogelj I
J Dairy Sci; 2016 Jul; 99(7):5008-5021. PubMed ID: 27157575
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
[TBL] [Abstract][Full Text] [Related]
5. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
[TBL] [Abstract][Full Text] [Related]
6. Xylo-oligosaccharides alone or in synbiotic combination with Bifidobacterium animalis subsp. lactis induce bifidogenesis and modulate markers of immune function in healthy adults: a double-blind, placebo-controlled, randomised, factorial cross-over study.
Childs CE; Röytiö H; Alhoniemi E; Fekete AA; Forssten SD; Hudjec N; Lim YN; Steger CJ; Yaqoob P; Tuohy KM; Rastall RA; Ouwehand AC; Gibson GR
Br J Nutr; 2014 Jun; 111(11):1945-56. PubMed ID: 24661576
[TBL] [Abstract][Full Text] [Related]
7. Microbiota Stability and Gastrointestinal Tolerance in Response to a High-Protein Diet with and without a Prebiotic, Probiotic, and Synbiotic: A Randomized, Double-Blind, Placebo-Controlled Trial in Older Women.
Ford AL; Nagulesapillai V; Piano A; Auger J; Girard SA; Christman M; Tompkins TA; Dahl WJ
J Acad Nutr Diet; 2020 Apr; 120(4):500-516.e10. PubMed ID: 32199523
[TBL] [Abstract][Full Text] [Related]
8. Improvement of gastrointestinal discomfort and inflammatory status by a synbiotic in middle-aged adults: a double-blind randomized placebo-controlled trial.
Neyrinck AM; Rodriguez J; Taminiau B; Amadieu C; Herpin F; Allaert FA; Cani PD; Daube G; Bindels LB; Delzenne NM
Sci Rep; 2021 Jan; 11(1):2627. PubMed ID: 33514774
[TBL] [Abstract][Full Text] [Related]
9. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial.
Mofidi F; Poustchi H; Yari Z; Nourinayyer B; Merat S; Sharafkhah M; Malekzadeh R; Hekmatdoost A
Br J Nutr; 2017 Mar; 117(5):662-668. PubMed ID: 28345499
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
Pierantonelli I; Svegliati-Baroni G
Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
12. Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics.
Krumbeck JA; Rasmussen HE; Hutkins RW; Clarke J; Shawron K; Keshavarzian A; Walter J
Microbiome; 2018 Jun; 6(1):121. PubMed ID: 29954454
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Probiotics (MCP
Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
[TBL] [Abstract][Full Text] [Related]
14. Synbiotic Effect of
Marsaux B; Van den Abbeele P; Ghyselinck J; Prioult G; Marzorati M; Bogićević B
Nutrients; 2020 Jul; 12(8):. PubMed ID: 32751149
[TBL] [Abstract][Full Text] [Related]
15. Probiotic or synbiotic alters the gut microbiota and metabolism in a randomised controlled trial of weight management in overweight adults.
Hibberd AA; Yde CC; Ziegler ML; Honoré AH; Saarinen MT; Lahtinen S; Stahl B; Jensen HM; Stenman LK
Benef Microbes; 2019 Mar; 10(2):121-135. PubMed ID: 30525950
[TBL] [Abstract][Full Text] [Related]
16. Effects of Synbiotic Supplement on Human Gut Microbiota, Body Composition and Weight Loss in Obesity.
Sergeev IN; Aljutaily T; Walton G; Huarte E
Nutrients; 2020 Jan; 12(1):. PubMed ID: 31952249
[TBL] [Abstract][Full Text] [Related]
17. Matrix Effects on the Delivery Efficacy of Bifidobacterium animalis subsp.
Ba Z; Lee Y; Meng H; Kris-Etherton PM; Rogers CJ; Lewis ZT; Mills DA; Furumoto EJ; Rolon ML; Fleming JA; Roberts RF
mSphere; 2021 Aug; 6(4):e0008421. PubMed ID: 34232082
[TBL] [Abstract][Full Text] [Related]
18. Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol.
Silva-Sperb AS; Moraes HA; de Moura BC; Alves BC; Bruch-Bertani JP; Azevedo VZ; Dall'Alba V
Trials; 2019 Oct; 20(1):580. PubMed ID: 31601229
[TBL] [Abstract][Full Text] [Related]
19. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.
Ye JZ; Li YT; Wu WR; Shi D; Fang DQ; Yang LY; Bian XY; Wu JJ; Wang Q; Jiang XW; Peng CG; Ye WC; Xia PC; Li LJ
World J Gastroenterol; 2018 Jun; 24(23):2468-2481. PubMed ID: 29930468
[TBL] [Abstract][Full Text] [Related]
20. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
